Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
bioAffinity Technologies, Inc. ( (BIAF) ) has provided an update.
On July 15, 2025, bioAffinity Technologies announced it received a notification of allowance from the China National Intellectual Property Administration for a patent related to predicting lung cancer likelihood using flow cytometry. This patent positions the company to expand its proprietary diagnostic platform in China, a significant market with a high prevalence of smokers and lung cancer cases. The patent protects the use of specific antibodies and porphyrin TCPP in labeling cell populations in sputum to detect lung cancer cells, enhancing the company’s global patent portfolio and supporting its strategy to build long-term shareholder value through innovation and early cancer detection.
The most recent analyst rating on (BIAF) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.
Spark’s Take on BIAF Stock
According to Spark, TipRanks’ AI Analyst, BIAF is a Neutral.
bioAffinity Technologies, Inc. faces financial instability with negative margins and cash flow, which are the most significant factors impacting the score. The technical analysis and valuation metrics are also concerning, with the stock trading below major moving averages and a negative P/E ratio. The corporate events highlight both risks related to Nasdaq compliance and potential improvements through new financial arrangements.
To see Spark’s full report on BIAF stock, click here.
More about bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. is a biotechnology company focused on noninvasive diagnostics for early-stage cancer and lung diseases, as well as broad-spectrum cancer treatments. Their primary product, CyPath® Lung, is a noninvasive test with high sensitivity, specificity, and accuracy for detecting early-stage lung cancer. It is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies.
Average Trading Volume: 7,147,163
Technical Sentiment Signal: Sell
Current Market Cap: $8.73M
See more insights into BIAF stock on TipRanks’ Stock Analysis page.